表紙
市場調查報告書

威爾姆氏腫瘤蛋白:開發中產品分析

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 516032
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
威爾姆氏腫瘤蛋白:開發中產品分析 Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 80 Pages
簡介

本報告提供以威爾姆氏腫瘤蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

威爾姆氏腫瘤蛋白;概要

威爾姆氏腫瘤蛋白;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc
  • 大塚集團
  • 大日本住友製藥
  • Vaximm AG

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2170TDB

Summary

Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Pancreatic Cancer, Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Leukemia, Lung Cancer, Melanoma, Solid Tumor, Adrenal Gland Cancer, Breast Cancer, Colorectal Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
  • The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Wilms Tumor Protein (WT33 or WT1) - Overview
  • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
  • Cue Biopharma Inc
  • Inovio Pharmaceuticals Inc
  • Scancell Holdings Plc
  • SELLAS Life Sciences Group Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • tella Inc
  • Vaximm AG
  • Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
  • Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CUE-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galinpepimut-S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INO-5401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ombipepimut-s - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TLP-0001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VXM-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Wilms Tumor Protein (WT33 or WT1) - Dormant Products
  • Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
  • Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 08, 2019: Boston Biomedical highlights phase 1 data evaluating investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) in patients with advanced malignancies at SITC 2019
  • Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
  • Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combination with PD-1 inhibitor Libtayo (cemiplimab)
  • Jul 31, 2019: SELLAS advances Galinpepimut-S (GPS) in combination with KEYTRUDA (pembrolizumab) program with dosing of first patient in phase 1/2 basket study
  • Apr 04, 2019: SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
  • Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
  • Feb 12, 2019: SELLAS Life Sciences provides Galinpepimut-S program update
  • Jan 29, 2019: John Theurer Cancer Center leading enrollment for global phase 2 WIZARD study evaluating DSP-7888 in patients with recurrent glioblastoma
  • Jan 08, 2019: SELLAS Life Sciences provides update on Galinpepimut-S (GPS)
  • Dec 20, 2018: Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology
  • Nov 28, 2018: SELLAS Life Sciences announces expedited development path for Galinpepimut-S (GPS) in acute myeloid leukemia (AML) following feedback from FDA
  • Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
  • Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
  • Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
  • Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Cue Biopharma Inc, H2 2019
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Pipeline by Scancell Holdings Plc, H2 2019
  • Pipeline by SELLAS Life Sciences Group Inc, H2 2019
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
  • Pipeline by tella Inc, H2 2019
  • Pipeline by Vaximm AG, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top